pyrazines has been researched along with sirolimus in 51 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (1.96) | 18.2507 |
| 2000's | 11 (21.57) | 29.6817 |
| 2010's | 35 (68.63) | 24.3611 |
| 2020's | 4 (7.84) | 2.80 |
| Authors | Studies |
|---|---|
| Berger, DP; Fiebig, HH; Plowman, J; Winterhalter, BR | 1 |
| von Mehren, M | 1 |
| Blasick, TM; Brown, RE; Lun, M; Siegelmann-Danieli, N; Zhang, PL | 1 |
| Frost, P; Gera, J; Lichtenstein, A; Shi, Y; Yan, H | 1 |
| Barete, S; Bodemer, C; Dubreuil, P; Georgin-Lavialle, S; Hermine, O; Lepelletier, Y; Lortholary, O; Suarez, F | 1 |
| López-Pérez, R; Montero, JC; Pandiella, A; San Miguel, JF | 1 |
| Ghori, N; Hanada, S; Harada, M; Omary, MB; Toivola, DM | 1 |
| Brossart, P; Fröhlich, E; Wahl, R | 1 |
| Delmonte, A; Ghielmini, M; Sessa, C | 1 |
| Benavides, A; Frost, P; Hoang, B; Lichtenstein, A; Shi, Y | 1 |
| Cho, HS; Kim, JS; Kim, KH; Kim, SJ; Kim, SY; Lee, JI; Lim, JH; Park, CG; Shin, JS; Shin, JY; Yoon, IH | 1 |
| Kahl, BS | 1 |
| Daniel, C; Gückel, E; Hugo, C; Meister, S; Starke, C; Stief, A; Vogelbacher, R; Voll, R; Wittmann, S | 1 |
| Kurzrock, R; Subbiah, V; Trent, JC | 1 |
| Gong, Y; Liu, T; Meng, W; Xing, H | 1 |
| Bendall, LJ; Bradstock, KF; Cisterne, A; Saunders, P; Weiss, J | 1 |
| He, XX; Huang, JJ; Huang, Y; Li, ZM; Lin, TY; Tian, Y; Xiao, J | 1 |
| Cavalli, F; Johnston, PB; Witzig, TE; Yuan, R | 1 |
| Anderson, KC; Armand, P; Bagshaw, M; Banwait, R; Chuma, S; Dollard, A; Ghobrial, IM; Harris, B; Jakubowiak, AJ; Kunsman, J; Laubach, J; Leduc, R; Maiso, P; Munshi, NC; Poon, T; Richardson, PG; Roccaro, A; Rodig, S; Sam, A; Schlossman, R; Vij, R; Warren, D; Weller, E | 1 |
| Nishi, S | 1 |
| Barrière, J; Janus, N; Launay-Vacher, V; Thariat, J | 1 |
| Brown, RE; Buryanek, J; Pfister, S; Rytting, ME; Vats, TS; Wolff, JE | 1 |
| Ramchandren, R | 1 |
| Blanco, B; Caballero-Velázquez, T; Calderon, C; Carrancio, S; del Cañizo, C; Gutierrez-Cosio, S; Herrero, C; Pérez-Simón, JA; San Miguel, JF; Sánchez-Abarca, LI; Serrano, C | 1 |
| Gao, D; Guo, K; Jiang, K; Jin, G; Kang, X; Li, Y; Liu, Y; Shu, H; Sun, C; Sun, H; Sun, L; Wang, C; Wu, W | 1 |
| Bitterman, PB; Dahlberg, PS; Issaenko, OA; Polunovsky, VA | 1 |
| Azab, AK; Azab, F; Banwait, R; Flores, L; Ghobrial, IM; Jia, X; Maiso, P; Manier, S; Roccaro, AM; Sacco, A | 1 |
| Camara-Clayette, V; Hermine, O; Ribrag, V | 1 |
| Ogura, M | 1 |
| Babcock, JT; He, Y; Hendricks, JW; Nguyen, HB; Quilliam, LA; Wek, RC | 1 |
| Chen, SS; Falchook, G; Fok, JY; Fu, S; Heymach, J; Hong, D; Janku, F; Kurzrock, R; Naing, A; Piha-Paul, S; Stephen, B; Tsimberidou, AM; Wheler, J | 1 |
| Chen, X; Chopra, R; Díaz-Rodríguez, E; Lopez-Girona, A; Miguel, JS; Mortensen, DS; Ocio, EM; Paiva, B; Pandiella, A | 1 |
| Bartlett, NL; Beck, JT; Cherfi, A; Cheung, W; Collins, RH; Fan, J; Fanning, SR; Goy, A; Johnston, PB; Kaminski, MS; Kaya, H; Klimovsky, J; Lister, J; O'Connor, OA; Popplewell, LL; Robeva, A; Tuscano, JM; Wang, M; Winter, JN | 1 |
| Choquet, S; Leblond, V; Nguyen, S; Souchet-Cömpain, L | 1 |
| Advani, RH; Anderson, KC; Barlogie, B; Dimopoulos, MA; García-Sanz, R; Gertz, MA; Ghobrial, IM; Gregory, SA; Kastritis, E; Kimby, E; Kyle, RA; Kyriakou, C; Landgren, O; Leblond, V; Leleu, X; Maloney, D; Merlini, G; Morel, P; Morra, E; Munshi, N; Owen, RG; Rummel, M; Terpos, E; Thomas, SK; Treon, SP | 1 |
| Barton, J; Bendell, JC; Burris, HA; Earwood, C; Hart, L; Infante, JR; Jones, SF; Lane, CM; Spigel, DR | 1 |
| Bartlett, DL; Kim, SY; Kwon, YT; Lee, YJ; Song, X; Tang, D; Zhang, L | 1 |
| Amaravadi, RK; Boyiadzis, M; Johnson, DE; Konig, H; Lotze, MT; Sehgal, AR; Tang, D | 1 |
| Castillo, JJ; Ghobrial, IM; Treon, SP | 1 |
| Chirgwin, JM; Suvannasankha, A | 1 |
| François, RA; Hochwald, SN; Kaye, FJ; Maeng, K; Nawab, A; Zajac-Kaye, M | 1 |
| Treon, SP | 1 |
| Auriemma, RS; Colao, A; Cuomo, G; de Angelis, C; De Martino, MC; Hofland, LJ; Izzo, F; Napolitano, M; Negri, M; Pivonello, C; Pivonello, R; Provvisiero, DP; Simeoli, C | 1 |
| Amin, HM; Benjamin, RS; Buford, AS; Daw, NC; Fokt, I; Lamhamedi-Cherradi, SE; Lazar, AJ; Ludwig, JA; Maywald, RL; Menegaz, BA; Mikos, AG; Naing, A; Priebe, W; Ramamoorthy, V; Ratan, R; Rohren, EM; Skora, S; Subbiah, V; Vishwamitra, D; Wang, J; Wang, Y | 1 |
| Anthony, LB; Carreira, VS; Chu, Z; Dahche, HM; Jiang, M; Koch, SE; Komurov, K; LaSance, K; Mercer, CA; Orr-Asman, MA; Plas, DR; Qi, X; Rubinstein, J; Thomas, HE; Worley, M | 1 |
| Atsriku, C; Li, Y; Liu, H; Narayanan, R; Nissel, J; Surapaneni, S; Tong, Z; Wang, X | 1 |
| Abhyankar, S; Kabadi, SM; Signorovitch, J; Song, J; Telford, C; Yao, Z; Zhao, J | 1 |
| Dong, L; Kothan, S; Liu, L; Moe, ATM; Pan, J; Sun, Y; Yang, Y | 1 |
| An, H; An, X; Chen, Y; Dai, X; Guan, S; Huang, B; Huang, Q; Liang, L; Lu, M; Lu, X; Nie, H; Wang, H; Wang, J; Wang, Z; Zhang, H | 1 |
| Abe, M; Kim, SB; Nishihara, R; Suzuki, K | 1 |
| Cai, JY; Du, HY; Jian, YL; Li, JL; Luo, H; Wang, R; Xie, XY; Yan, R | 1 |
14 review(s) available for pyrazines and sirolimus
| Article | Year |
|---|---|
New therapeutic strategies for soft tissue sarcomas.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials as Topic; Dioxoles; Docetaxel; Epothilones; Guanidines; Humans; Indoles; Isoquinolines; Protein Kinase Inhibitors; Protein Kinases; Pyrazines; Pyrroles; Sarcoma; Sirolimus; Sunitinib; Taxoids; Tetrahydroisoquinolines; TOR Serine-Threonine Kinases; Trabectedin | 2003 |
[Current concepts and treatment advances in systemic mastocytosis].
Topics: Adult; Boronic Acids; Bortezomib; Child; Forecasting; Humans; Immunohistochemistry; Immunosuppressive Agents; Mastocytosis, Systemic; Mutation; Prognosis; Protease Inhibitors; Proto-Oncogene Proteins c-kit; Pyrazines; Sirolimus; Stem Cell Transplantation; Transduction, Genetic; World Health Organization | 2009 |
Beyond monoclonal antibodies: new therapeutic agents in non-Hodgkin's lymphomas.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Boronic Acids; Bortezomib; Clinical Trials as Topic; Histone Deacetylase Inhibitors; HSP90 Heat-Shock Proteins; Humans; Lymphoma, Non-Hodgkin; Oligonucleotides, Antisense; Proteasome Inhibitors; Protein Kinase C; Pyrazines; Sirolimus | 2009 |
Frontline therapy in mantle cell lymphoma: the role of high-dose therapy and integration of new agents.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Boronic Acids; Bortezomib; Combined Modality Therapy; Humans; Lymphoma, Mantle-Cell; Nitrogen Mustard Compounds; Pyrazines; Radioimmunotherapy; Sirolimus; Survival Analysis; Treatment Outcome | 2009 |
Targeted therapy in lymphoma.
Topics: Boronic Acids; Bortezomib; Everolimus; Humans; Lymphoma; Molecular Targeted Therapy; Pyrazines; Signal Transduction; Sirolimus; Survival Analysis | 2010 |
[Immunosuppressive agents in kidney transplantation].
Topics: Antibodies; Antibodies, Monoclonal, Murine-Derived; Boronic Acids; Bortezomib; Cyclosporine; Everolimus; Fingolimod Hydrochloride; Graft Rejection; Immunosuppressive Agents; Kidney Transplantation; Propylene Glycols; Pyrazines; Rituximab; Sirolimus; Sphingosine; T-Lymphocytes; Tacrolimus; TOR Serine-Threonine Kinases | 2011 |
Advances in the treatment of relapsed or refractory Hodgkin's lymphoma.
Topics: Antibodies, Monoclonal, Murine-Derived; Boronic Acids; Bortezomib; Brentuximab Vedotin; Drug Therapy; Everolimus; Histone Deacetylase Inhibitors; Hodgkin Disease; Humans; Immunoconjugates; Immunotherapy; Lenalidomide; Protease Inhibitors; Pyrazines; Recurrence; Rituximab; Secondary Prevention; Sirolimus; Thalidomide | 2012 |
Emerging agents for the treatment of mantle cell lymphoma.
Topics: Adult; Age Factors; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cytarabine; Disease-Free Survival; Dose-Response Relationship, Drug; Drugs, Investigational; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, Mantle-Cell; Molecular Targeted Therapy; Prognosis; Pyrazines; Recurrence; Salvage Therapy; Sirolimus; Survival Analysis; TOR Serine-Threonine Kinases; Treatment Outcome; Watchful Waiting | 2012 |
Current and future therapeutic approach for Waldenström's macroglobulinemia.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Comorbidity; Disease Progression; Everolimus; Forecasting; Guillain-Barre Syndrome; Hematopoietic Stem Cell Transplantation; Histone Deacetylase Inhibitors; Humans; Immunologic Factors; Immunotherapy; Incidence; Lenalidomide; Myelin-Associated Glycoprotein; Protein Kinase Inhibitors; Pyrazines; Rituximab; Salvage Therapy; Sirolimus; Thalidomide; Transplantation, Autologous; Treatment Outcome; Waldenstrom Macroglobulinemia; Watchful Waiting | 2014 |
Treatment recommendations for patients with Waldenström macroglobulinemia (WM) and related disorders: IWWM-7 consensus.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Bendamustine Hydrochloride; Boronic Acids; Bortezomib; Clinical Trials as Topic; Consensus Development Conferences as Topic; Disease Progression; Everolimus; Hematopoietic Stem Cell Transplantation; Humans; Immunologic Factors; Nitrogen Mustard Compounds; Pyrazines; Rituximab; Salvage Therapy; Sirolimus; Treatment Outcome; Vidarabine; Waldenstrom Macroglobulinemia | 2014 |
You eat what you are: autophagy inhibition as a therapeutic strategy in leukemia.
Topics: Antineoplastic Agents; Autophagy; Boronic Acids; Bortezomib; Cell Survival; Clinical Trials as Topic; Drug Resistance, Neoplasm; Gene Expression; HMGB1 Protein; Humans; Hydroxychloroquine; Leukemia; Leukocytes; Lysosomes; Phagosomes; Pyrazines; Sirolimus | 2015 |
Biology, prognosis, and therapy of Waldenström Macroglobulinemia.
Topics: Adenine; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Boronic Acids; Bortezomib; Everolimus; Humans; Piperidines; Prognosis; Proteasome Inhibitors; Pyrazines; Pyrazoles; Pyrimidines; Salvage Therapy; Sirolimus; Stem Cell Transplantation; Waldenstrom Macroglobulinemia | 2015 |
Role of bone-anabolic agents in the treatment of breast cancer bone metastases.
Topics: Antineoplastic Agents; Bone Density Conservation Agents; Bone Neoplasms; Boronic Acids; Bortezomib; Breast Neoplasms; Everolimus; Female; Humans; Oligopeptides; Osteoblasts; Parathyroid Hormone; Proteasome Inhibitors; Pyrazines; Recombinant Fusion Proteins; Sirolimus; Thiophenes; Transforming Growth Factor beta | 2014 |
Matching-adjusted Indirect Comparisons of the Efficacy and Safety of Acalabrutinib Versus Other Targeted Therapies in Relapsed/Refractory Mantle Cell Lymphoma.
Topics: Adenine; Antineoplastic Agents; Benzamides; Bortezomib; Humans; Lenalidomide; Lymphoma, Mantle-Cell; Neoplasm Recurrence, Local; Piperidines; Pyrazines; Pyrazoles; Pyrimidines; Rituximab; Sirolimus; Treatment Outcome | 2019 |
6 trial(s) available for pyrazines and sirolimus
| Article | Year |
|---|---|
Weekly bortezomib in combination with temsirolimus in relapsed or relapsed and refractory multiple myeloma: a multicentre, phase 1/2, open-label, dose-escalation study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Boronic Acids; Bortezomib; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Multiple Myeloma; Pyrazines; Recurrence; Sirolimus | 2011 |
Preliminary experience with personalized and targeted therapy for pediatric brain tumors.
Topics: Adolescent; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Bevacizumab; Biomarkers, Tumor; Boronic Acids; Bortezomib; Brain Neoplasms; Child; Child, Preschool; Curcumin; Disease-Free Survival; Estradiol; Female; Follow-Up Studies; Fulvestrant; Humans; Infant; Male; Niacinamide; Phenylurea Compounds; Pyrazines; Pyridines; Sirolimus; Sorafenib; Survival Rate | 2012 |
[Current development of new drugs in malignant lymphoma].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bendamustine Hydrochloride; Boronic Acids; Bortezomib; Brentuximab Vedotin; Diphtheria Toxin; Drug Discovery; Everolimus; Humans; Hydroxamic Acids; Immunoconjugates; Indoles; Inotuzumab Ozogamicin; Interleukin-2; Lenalidomide; Lymphoma; Lymphoma, B-Cell; Nitrogen Mustard Compounds; Purine Nucleosides; Pyrazines; Pyrimidinones; Recombinant Fusion Proteins; Sirolimus; Thalidomide; Vorinostat | 2012 |
Revisiting clinical trials using EGFR inhibitor-based regimens in patients with advanced non-small cell lung cancer: a retrospective analysis of an MD Anderson Cancer Center phase I population.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Boronic Acids; Bortezomib; Carcinoma, Non-Small-Cell Lung; Cetuximab; Dasatinib; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Pyrazines; Pyrimidines; Quinazolines; Retrospective Studies; Sirolimus; Survival; Thiazoles; Treatment Outcome | 2013 |
Everolimus for patients with mantle cell lymphoma refractory to or intolerant of bortezomib: multicentre, single-arm, phase 2 study.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy; Disease-Free Survival; Drug Resistance, Neoplasm; Everolimus; Female; Gastrointestinal Diseases; Hematologic Diseases; Humans; Kaplan-Meier Estimate; Lymphoma, Mantle-Cell; Male; Middle Aged; Pain; Pneumonia; Pyrazines; Salvage Therapy; Sirolimus; Treatment Outcome | 2014 |
A phase Ib study of linsitinib (OSI-906), a dual inhibitor of IGF-1R and IR tyrosine kinase, in combination with everolimus as treatment for patients with refractory metastatic colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Everolimus; Female; Humans; Imidazoles; Male; Maximum Tolerated Dose; Middle Aged; Protein Kinase Inhibitors; Pyrazines; Receptor, IGF Type 1; Sirolimus | 2015 |
31 other study(ies) available for pyrazines and sirolimus
| Article | Year |
|---|---|
In vitro and in vivo evaluation of US-NCI compounds in human tumor xenografts.
Topics: Animals; Anthracyclines; Antibiotics, Antineoplastic; Antineoplastic Agents; Drug Screening Assays, Antitumor; Female; Humans; Mice; Mice, Nude; National Institutes of Health (U.S.); Neoplasm Transplantation; Picolines; Polyenes; Pyrazines; Sirolimus; Sulfonic Acids; Terpenes; Tumor Stem Cell Assay; United States | 1990 |
Pamidronate resistance and associated low ras levels in breast cancer cells: a role for combinatorial therapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzamides; Boronic Acids; Bortezomib; Breast Neoplasms; Carcinoma; Cell Line, Tumor; Cell Proliferation; Diphosphonates; Drug Combinations; Drug Resistance, Neoplasm; Female; Humans; Imatinib Mesylate; Pamidronate; Piperazines; Pyrazines; Pyrimidines; ras Proteins; Sirolimus | 2004 |
Mammalian target of rapamycin inhibitors activate the AKT kinase in multiple myeloma cells by up-regulating the insulin-like growth factor receptor/insulin receptor substrate-1/phosphatidylinositol 3-kinase cascade.
Topics: Animals; Antibiotics, Antineoplastic; Apoptosis; Boronic Acids; Bortezomib; Cell Line, Tumor; Enzyme Activation; Humans; Insulin Receptor Substrate Proteins; Insulin-Like Growth Factor I; Mice; Mice, SCID; Multiple Myeloma; Phosphatidylinositol 3-Kinases; Phosphoproteins; Protein Kinase Inhibitors; Protein Kinases; Proto-Oncogene Proteins c-akt; Pyrazines; Receptor, IGF Type 1; Sirolimus; TOR Serine-Threonine Kinases; Xenograft Model Antitumor Assays | 2005 |
Expression of c-Kit isoforms in multiple myeloma: differences in signaling and drug sensitivity.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Cell Death; Cell Line; Cell Line, Tumor; Gene Expression Regulation, Neoplastic; Humans; Immunophenotyping; Melphalan; Multiple Myeloma; Protein Isoforms; Protein Kinases; Proto-Oncogene Proteins c-kit; Pyrazines; Signal Transduction; Sirolimus; TOR Serine-Threonine Kinases | 2008 |
Autophagy activation by rapamycin eliminates mouse Mallory-Denk bodies and blocks their proteasome inhibitor-mediated formation.
Topics: Animals; Autophagy; Boronic Acids; Bortezomib; Cell Line, Tumor; Hepatocytes; Humans; Immunosuppressive Agents; Inclusion Bodies; Keratin-8; Mice; Mice, Knockout; Mice, Transgenic; Models, Animal; Protease Inhibitors; Proteasome Inhibitors; Pyrazines; Sirolimus; Transfection | 2008 |
Induction of iodide uptake in transformed thyrocytes: a compound screening in cell lines.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Boronic Acids; Bortezomib; Carcinoma; Cell Differentiation; Cell Line, Tumor; Cell Proliferation; Drug Screening Assays, Antitumor; Humans; Iodides; Lovastatin; Neoplasm Metastasis; Oxides; Pyrazines; Sirolimus; Thymus Gland; Thyroid Neoplasms; Tretinoin | 2009 |
Effect of autophagy on multiple myeloma cell viability.
Topics: Adenine; Antifungal Agents; Antimalarials; Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Autophagy; Beclin-1; Boronic Acids; Bortezomib; Cell Proliferation; Chloroquine; Drug Therapy, Combination; Enzyme Inhibitors; Humans; Immunoblotting; Membrane Proteins; Microscopy, Fluorescence; Multiple Myeloma; Pyrazines; RNA, Small Interfering; Sirolimus; Thapsigargin; Tumor Cells, Cultured | 2009 |
Bortezomib can suppress activation of rapamycin-resistant memory T cells without affecting regulatory T-cell viability in non-human primates.
Topics: Animals; Boronic Acids; Bortezomib; Cell Proliferation; Cell Survival; Disease Models, Animal; Drug Resistance; Graft Rejection; Immunologic Memory; Immunosuppressive Agents; Lymphocyte Activation; Macaca mulatta; Male; Pancreas Transplantation; Protease Inhibitors; Pyrazines; Sirolimus; Swine; Swine, Miniature; T-Lymphocytes; T-Lymphocytes, Regulatory | 2009 |
Bortezomib and sirolimus inhibit the chronic active antibody-mediated rejection in experimental renal transplantation in the rat.
Topics: Animals; Boronic Acids; Bortezomib; Chronic Disease; Graft Rejection; Immunosuppressive Agents; Isoantibodies; Kidney Transplantation; Lymphocyte Depletion; Male; Plasma Cells; Pyrazines; Rats; Rats, Inbred F344; Rats, Inbred Lew; Sirolimus; Spleen; T-Lymphocytes; Transplantation, Homologous | 2010 |
Resistance to mammalian target of rapamycin inhibitor therapy in perivascular epithelioid cell tumors.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Chemotherapy, Adjuvant; Clinical Trials, Phase I as Topic; Disease Progression; Doxorubicin; Drug Resistance, Neoplasm; Female; Humans; Intracellular Signaling Peptides and Proteins; Middle Aged; Perivascular Epithelioid Cell Neoplasms; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Pyrazines; Retroperitoneal Neoplasms; Sirolimus; Topotecan; TOR Serine-Threonine Kinases; Treatment Failure | 2010 |
An investigation of reversal of imatinib resistance in the Bcr-Abl positive imatinib-resistant cell line K562r by dasatinib, nilotinib, rapamycin and bortezomib.
Topics: Antineoplastic Agents; Benzamides; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Proliferation; Dasatinib; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; K562 Cells; Piperazines; Pyrazines; Pyrimidines; Signal Transduction; Sirolimus; Thiazoles; TOR Serine-Threonine Kinases; Up-Regulation | 2011 |
The mammalian target of rapamycin inhibitor RAD001 (everolimus) synergizes with chemotherapeutic agents, ionizing radiation and proteasome inhibitors in pre-B acute lymphocytic leukemia.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cell Line, Tumor; Combined Modality Therapy; Everolimus; Humans; Immunosuppressive Agents; Leupeptins; Mice; Mice, Inbred NOD; Mice, SCID; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Prognosis; Protease Inhibitors; Pyrazines; Radiation, Ionizing; Sirolimus; Survival Rate; TOR Serine-Threonine Kinases; Whole-Body Irradiation | 2011 |
Schedule-dependent inhibition of T-cell lymphoma cells by cotreatment with the mTOR inhibitor everolimus and anticancer drugs.
Topics: Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Boronic Acids; Bortezomib; Cell Cycle; Cell Proliferation; Dose-Response Relationship, Drug; Doxorubicin; Drug Synergism; Etoposide; Everolimus; Humans; Jurkat Cells; Lymphoma, T-Cell; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; PTEN Phosphohydrolase; Pyrazines; Sirolimus; Time Factors; TOR Serine-Threonine Kinases; Vincristine | 2012 |
[Renal tolerance of targeted therapies].
Topics: Antibodies, Monoclonal; Benzenesulfonates; Boronic Acids; Bortezomib; Erlotinib Hydrochloride; Glomerulonephritis; Humans; Indoles; Kidney; Kidney Tubules; Lapatinib; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrazines; Pyridines; Pyrroles; Quinazolines; Sirolimus; Sorafenib; Sunitinib | 2012 |
The novel combination of sirolimus and bortezomib prevents graft-versus-host disease but maintains the graft-versus-leukemia effect after allogeneic transplantation.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Bone Marrow Transplantation; Boronic Acids; Bortezomib; Cell Proliferation; Cytokines; Female; Flow Cytometry; Graft vs Host Disease; Graft vs Tumor Effect; Leukemia, Experimental; Male; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Mice, Inbred NOD; Pyrazines; Sirolimus; T-Lymphocytes; T-Lymphocytes, Regulatory; Transplantation, Homologous | 2012 |
Novel synergistic antitumor effects of rapamycin with bortezomib on hepatocellular carcinoma cells and orthotopic tumor model.
Topics: Animals; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Movement; Cell Proliferation; Drug Synergism; Humans; Liver Neoplasms; Lung Neoplasms; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Neovascularization, Pathologic; Proto-Oncogene Proteins c-akt; Pyrazines; Sirolimus; TOR Serine-Threonine Kinases; Tumor Burden; Tumor Suppressor Protein p53; Xenograft Model Antitumor Assays | 2012 |
Cap-dependent mRNA translation and the ubiquitin-proteasome system cooperate to promote ERBB2-dependent esophageal cancer phenotype.
Topics: Adaptor Proteins, Signal Transducing; Apoptosis; Boronic Acids; Bortezomib; Case-Control Studies; Cell Cycle Proteins; Cell Line, Tumor; Cell Proliferation; Drug Synergism; Enzyme Activation; Esophageal Neoplasms; Eukaryotic Initiation Factor-4F; Feedback, Physiological; Gene Expression Regulation, Neoplastic; Gene Silencing; Gene Targeting; Humans; Phenotype; Phosphoproteins; Phosphorylation; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Protein Biosynthesis; Proteolysis; Pyrazines; Receptor, ErbB-2; Repressor Proteins; RNA Caps; RNA, Messenger; RNA, Small Interfering; Sirolimus; Ubiquitin | 2012 |
Mechanisms of activity of the TORC1 inhibitor everolimus in Waldenstrom macroglobulinemia.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Apoptosis; Bone Marrow; Boronic Acids; Bortezomib; Cell Cycle; Cell Proliferation; Cell Survival; Clinical Trials, Phase II as Topic; Drug Synergism; Everolimus; Humans; Mechanistic Target of Rapamycin Complex 1; MicroRNAs; Multiprotein Complexes; Pyrazines; Rituximab; Signal Transduction; Sirolimus; TOR Serine-Threonine Kinases; Treatment Outcome; Tumor Cells, Cultured; Tumor Microenvironment; Waldenstrom Macroglobulinemia | 2012 |
Mammalian target of rapamycin complex 1 (mTORC1) enhances bortezomib-induced death in tuberous sclerosis complex (TSC)-null cells by a c-MYC-dependent induction of the unfolded protein response.
Topics: Activating Transcription Factor 4; Animals; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Cell Line, Tumor; Gene Expression Regulation; Humans; Immunosuppressive Agents; Mechanistic Target of Rapamycin Complex 1; Multiprotein Complexes; Protein Biosynthesis; Proteins; Proto-Oncogene Proteins c-myc; Pyrazines; Rats; Signal Transduction; Sirolimus; TOR Serine-Threonine Kinases; Transcription Factor CHOP; Tuberous Sclerosis Complex 1 Protein; Tuberous Sclerosis Complex 2 Protein; Tumor Suppressor Proteins; Unfolded Protein Response | 2013 |
Genetic and pharmacologic evidence that mTOR targeting outweighs mTORC1 inhibition as an antimyeloma strategy.
Topics: Antibiotics, Antineoplastic; Apoptosis; Blotting, Western; Cell Cycle Checkpoints; Cell Line; Cell Proliferation; Cell Survival; Coculture Techniques; Dose-Response Relationship, Drug; HEK293 Cells; Humans; Imidazoles; Mechanistic Target of Rapamycin Complex 1; Mechanistic Target of Rapamycin Complex 2; Multiple Myeloma; Multiprotein Complexes; Pyrazines; RNA Interference; Signal Transduction; Sirolimus; Stromal Cells; TOR Serine-Threonine Kinases; Tumor Cells, Cultured | 2014 |
Role of AMP-activated protein kinase in cross-talk between apoptosis and autophagy in human colon cancer.
Topics: AMP-Activated Protein Kinases; Animals; Apoptosis; Apoptosis Regulatory Proteins; Autophagy; Beclin-1; Boronic Acids; Bortezomib; Cell Line, Tumor; Colonic Neoplasms; Drug Synergism; Enzyme Activation; Humans; Kinetics; Melphalan; Membrane Proteins; Mice; Mitochondria; Phosphorylation; Phosphoserine; Pyrazines; Sirolimus | 2014 |
Targeting Focal Adhesion Kinase and Resistance to mTOR Inhibition in Pancreatic Neuroendocrine Tumors.
Topics: Animals; Antineoplastic Agents; Apoptosis; Benzamides; Carcinoma; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Resistance, Neoplasm; Drug Synergism; Everolimus; Female; Focal Adhesion Kinase 1; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Humans; Male; Mice; Mice, Inbred NOD; Mice, SCID; Molecular Targeted Therapy; Neuroendocrine Tumors; Organic Chemicals; Pancreatic Neoplasms; Peritoneal Neoplasms; Protein Kinase Inhibitors; Pyrazines; Signal Transduction; Sirolimus; Sulfonamides; TOR Serine-Threonine Kinases; Up-Regulation; Xenograft Model Antitumor Assays | 2015 |
How I treat Waldenström macroglobulinemia.
Topics: Adenine; Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; B-Lymphocytes; Bendamustine Hydrochloride; Boronic Acids; Bortezomib; Cladribine; Cyclophosphamide; Everolimus; Gene Expression; Genetic Predisposition to Disease; Hematopoietic Stem Cell Transplantation; Humans; Immunoglobulin M; Male; Middle Aged; Molecular Targeted Therapy; Myeloid Differentiation Factor 88; Nitrogen Mustard Compounds; Oligopeptides; Piperidines; Plasmapheresis; Pyrazines; Pyrazoles; Pyrimidines; Receptors, CXCR4; Rituximab; Sirolimus; Transplantation, Autologous; Vidarabine; Waldenstrom Macroglobulinemia | 2015 |
The dual targeting of insulin and insulin-like growth factor 1 receptor enhances the mTOR inhibitor-mediated antitumor efficacy in hepatocellular carcinoma.
Topics: alpha-Fetoproteins; Antineoplastic Agents; Apoptosis; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Survival; Drug Combinations; Everolimus; Extracellular Signal-Regulated MAP Kinases; G1 Phase Cell Cycle Checkpoints; Hep G2 Cells; Humans; Imidazoles; Insulin; Liver Neoplasms; Proto-Oncogene Proteins c-akt; Pyrazines; Receptor, IGF Type 1; Receptors, Somatomedin; Ribosomal Protein S6 Kinases, 70-kDa; RNA, Messenger; Sirolimus; TOR Serine-Threonine Kinases | 2016 |
IGF-1R and mTOR Blockade: Novel Resistance Mechanisms and Synergistic Drug Combinations for Ewing Sarcoma.
Topics: Adenosine Triphosphatases; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Cation Transport Proteins; Cell Line, Tumor; Copper-Transporting ATPases; Drug Resistance, Neoplasm; Drug Synergism; Humans; Imidazoles; Insulin Receptor Substrate Proteins; Male; Mice; Mice, SCID; Neoplasm Transplantation; Nucleocytoplasmic Transport Proteins; p38 Mitogen-Activated Protein Kinases; Phosphatidylinositol 3-Kinase; Phosphoinositide-3 Kinase Inhibitors; Protein Array Analysis; Pyrazines; Pyrimidines; Pyrroles; Receptor, IGF Type 1; Receptors, Somatomedin; Sarcoma, Ewing; Sirolimus; STAT3 Transcription Factor; TOR Serine-Threonine Kinases; Up-Regulation | 2016 |
mTOR Kinase Inhibition Effectively Decreases Progression of a Subset of Neuroendocrine Tumors that Progress on Rapalog Therapy and Delays Cardiac Impairment.
Topics: Animals; Carcinoid Heart Disease; Cell Line, Tumor; Drug Resistance, Neoplasm; Everolimus; Gene Expression Regulation, Neoplastic; Humans; Mice; Neuroendocrine Tumors; Pancreatic Neoplasms; Protein Kinase Inhibitors; Pyrazines; Sirolimus; TOR Serine-Threonine Kinases; Xenograft Model Antitumor Assays | 2017 |
Assessment of drug-drug interaction potential and PBPK modeling of CC-223, a potent inhibitor of the mammalian target of rapamycin kinase.
Topics: Animals; Cytochrome P-450 CYP3A Inhibitors; Cytochrome P-450 Enzyme System; Drug Interactions; Humans; Ketoconazole; Membrane Transport Proteins; Microsomes, Liver; Prospective Studies; Pyrazines; Sirolimus; TOR Serine-Threonine Kinases | 2019 |
Autophagy participants in the dedifferentiation of mouse 3T3-L1 adipocytes triggered by hypofunction of insulin signaling.
Topics: 3T3-L1 Cells; Adipocytes; Animals; Autophagy; Cell Dedifferentiation; Imidazoles; Insulin; Insulin-Like Growth Factor I; Macrolides; Mechanistic Target of Rapamycin Complex 1; Mice; Proto-Oncogene Proteins c-akt; Pyrazines; Signal Transduction; Sirolimus | 2021 |
Transcriptome and lipidome profile of human mesenchymal stem cells with reduced senescence and increased trilineage differentiation ability upon drug treatment.
Topics: Ascorbic Acid; Cell Differentiation; Cellular Senescence; Humans; Hypoglycemic Agents; Lipidomics; Mesenchymal Stem Cells; Metformin; Pyrazines; Reverse Transcriptase Inhibitors; Sirolimus; Thiones; Thiophenes; Transcriptome | 2021 |
Luciferase-Specific Coelenterazine Analogues for Optical Cross Talk-Free Bioassays.
Topics: Alkynes; Animals; Chlorocebus aethiops; COS Cells; Estrogen Receptor Modulators; Imidazoles; Immunosuppressive Agents; Luciferases; Luminescent Agents; Luminescent Measurements; Optical Imaging; Pyrazines; Sirolimus; Styrenes | 2021 |
Ligustrazine protects against chronic hypertensive glaucoma in rats by inhibiting autophagy via the PI3K-Akt/mTOR pathway.
Topics: Animals; Apoptosis; Autophagy; Glaucoma; Humans; Phosphatidylinositol 3-Kinase; Proto-Oncogene Proteins c-akt; Pyrazines; Rats; Rats, Sprague-Dawley; Retinal Ganglion Cells; Sirolimus; TOR Serine-Threonine Kinases | 2021 |